SFB 1243 Cancer Evolution

Breadcrumb Navigation


A10 Identifying and targeting escape mechanisms in AML using multispecific antibody derivatives

The major challenge in the treatment of acute myeloid leukemia (AML) is the prevention of relapse due to refractory leukemic stem cells (LSC). The project aims to identify and counteract the evolution of immune resistance of LSCs. We will profile residual and relapsed leukemic cells after allogeneic stem cell transplantation or after antibody therapy to identify resistance mechanisms. Multispecific antibodies will be engineered to simultaneously target LSCs and limit immune escape based on the knowledge of leukemic evolution.

a10 subklewe 735

Hopfner, Karl-Peter

Prof. Dr. Karl-Peter Hopfner

Genzentrum, Department Biochemie, Ludwig-maximilians-Universität München

+49 (0)89 2180-76953


Subklewe, Marion

Prof. Dr. Marion Subklewe

Medizinische Klinik und Poliklinik III, Ludwig-Maximilians-Universität München Gene Center Munich

+49 (0)89 44007-3133 (hospital), +49( 0)89 2180 76875 (lab)